One hundred and fifty-three authors, 45 Italian scientific societies, and two Italian patients' associations participated in drafting the Italian Stroke Organization document, which has become the national guideline for the prevention and treatment of stroke in Italy. For the surgical therapy section of the Italian Stroke Organization document, the main trials on carotid endoarterectomy and stenting were critically reviewed in order to formulate recommendations for these procedures. Recommendations are presented here for the referral of patients to either carotid endarterectomy or stenting on the basis of whether carotid stenosis is symptomatic or asymptomatic.
Introduction
Thirteen years after its first edition, the Italian Stroke Organization (ISO) document -previously called the Stroke Prevention and Educational Awareness Diffusion (SPREAD) document -has become consolidated as the national guideline for the prevention and treatment of stroke in Italy (1) . In order to draw its recommendations, a multidisciplinary team of authors -representing Italian scientific societies in the neurology, neuroradiology, vascular and endovascular surgery, interventional cardiology, and general medicine fields -examined the literature available on stroke. One hundred and fifty-three authors, 45 scientific societies, and two patients' associations participated in drafting the seventh edition in 2012. The document includes the following sections: methodology, diagnosis, risk factors, primary prevention, acute phase from pre-hospitalization to hospitalization, secondary prevention and long-term pharmacological therapy, surgical therapy of the carotid artery, rehabilitation, psychocognitive complications, multidisciplinary research, and bioethical and economic concerns. The recommendations of the document were discussed, approved, and implemented during plenary meetings of the authors. The completed ISO document was then approved by the scientific societies and the patients' associations.
An expert panel from the National Stroke Association recognized the SPREAD document as one of nine guidelines containing valid recommendations among 257 documents examined in total (2) . Out of the 53 unique recommendations finally selected from these nine guidelines, 14 originated from the SPREAD document. These recommendations were mainly from the carotid surgery section of the document. For the present update, we have extrapolated recommendations for the surgical treatment of carotid stenosis (CS) and, in particular, for practice concerning carotid endarterectomy (CEA) and carotid artery stenting (CAS) (Box 1).
Methodology
Studies were collated from direct searches of MEDLINE via PubMed, the Cochrane Database of Systematic Reviews, and Clinical Evidence. Data obtained from Italian and/or international sources directly available to the authors were also considered. In addition, documented opinion on still unresolved issues, even when not upheld by specifically collected evidence, was used and identified as such.
The Scottish Intercollegiate Guideline Network system (3) was followed to grade the recommendations, which were integrated with statistical considerations grounded on the Oxford Centre for Evidence-Based Medicine (4). The following steps were followed to develop the recommendations: • preparation of the text of the recommendations, including the good practice points based on the clinical experience and consensus of the task force members. Table 1 sets out the evidence levels and grading criteria used to assess each recommendation. NASCET (5) and ECST (6) are considered the landmark largescale randomized studies conducted to date in symptomatic patients. Those studies demonstrated that symptomatic patientsdefined as having had at least one episode of transient ischemic attack (TIA) or minor stroke within the previous six-months (set by convention) -benefited more from CEA than from medical therapy alone, in terms of reduced risk of stroke, death, and myocardial infarction (MI), if stenosis was >70% (the degree of carotid narrowing from here on is given as based on the NASCET criteria). In contrast, disadvantages were reported for CEA in patients with <50% CS; thus, CEA was not recommended for this category of patients. Where CEA was beneficial, some subgroups of patients were found to benefit more than others (5) (6) (7) . In line with these findings, a previous systematic review of the Cochrane Collaboration demonstrated the benefit of CEA when narrowing was at least 50% (8) . Moreover, a meta-analysis reported that surgery increased the risk of ipsilateral stroke at five-years if CS was <30%, did not produce significant effects if CS was 30-49%, was marginally beneficial if CS was 50-69%, and markedly beneficial for 70-99% CS in the absence of near occlusion (9) . In any case, benefit from CEA has been correlated with the perioperative risk for major cardiocerebrovascular complications -such as death, stroke, and MI -which should be less than 6% (5, 6) . A recent systematic review reported that these data from NASCET and ECST are still valid (10) . Importantly, age is not a limiting factor for surgical treatment (11) . In fact, the incidence of symptomatic CS increases with age and, therefore, it is mainly older patients that benefit from surgery. Unfortunately, clinicians tend not to routinely refer those over 80 years of age to diagnosis of CS (12) . A variety of other clinical and pathological factors have to be taken into consideration when formulating new models to optimize referral of symptomatic patients to CEA. This was pointed out in NASCET, in which the incidence of stroke at 24 months for medically treated patients with 70-99% CS was reported to be 17% for amaurosis fugax and 44% for hemispheric symptoms (13) . Rothwell and Warlow have attempted to evaluate which factors could best predict risk/benefit with medical or surgical treatment (14) .
Results

CEA in symptomatic patients
Other criteria seem less important for impacting CEA, such as the presence of lacunar infarcts, which have been reported to be only coincidental with CS (15), whereas still other concurrent pathologies may have more complex effects, such as leukoaraiosis, which increases the perioperative risk but also benefits more from surgical intervention (16) .
The advantages of CEA have been correlated also to other factors, such as the delay-to-surgery from the first presenting event. In fact, Rothwell et al. re-analyzed ECST and NASCET datasets and found that the benefit of surgery is greatest for patients randomized to CEA within two-weeks from the initial ischemic event (17) . It is well known that there is a high risk of recurrent stroke in the first few days after a TIA/minor stroke (18) (19) (20) (21) . Regarding the periprocedural risk of CEA performed in the first week, this is not substantially higher than that for delayed surgery (22) .
Even if the populations studied were not completely homogeneous for degree of CS, the advantages of CEA declined to near zero -or at least to lower than that found in studies on asymptomatic patients -after 12 weeks. We believe, therefore, that it is necessary to reduce the interval of time set at six-months by ECST and NASCET to no more than three-months from the last ischemic episode when classifying CS as symptomatic.
CEA in asymptomatic patients
The usefulness of surgery for asymptomatic patients is still a matter of debate, even after the publication of positive findings by ACAS (23) . ACAS reported that 'asymptomatic' CS patients ben-efited from CEA if narrowing was ≥60%. However, the advantages of CEA were evident only after a two-year follow-up period, becoming more significant at five-years only when surgery was performed with a perioperative morbidity and mortality of <3% (24, 25) . Nevertheless, several authors have concluded that even if CEA in this setting reduces the incidence of ipsilateral stroke, it has low absolute benefit (26, 27) . Therefore, this kind of surgery should not be routinely recommended if the patient is not in a subgroup classified 'high risk' . Criticisms have been directed to many of the conclusions of the ACAS report (28) (29) (30) (31) (32) (33) . In contrast, ACST confirmed the benefit of CEA in patients under 75 years of age with asymptomatic ≥70% CS when the perioperative risk was <3% (34) (35) (36) .
Many studies have reported that the natural progression of patients with asymptomatic, hemodynamically significant CS includes a risk for nondisabling stroke and a somewhat lower risk for disabling stroke without warning symptoms, estimated in the literature as <5% per year (37, 38) . Moreover, these patients are subject to an increased risk of MI and nonstroke vascular deaths, which necessitate more global preventive treatments (39) . Therefore, it is necessary to identify subgroups of asymptomatic CS patients that are at greater risk of ipsilateral stroke if not referred to CEA. It has already been demonstrated that the best medical therapy (BMT) can effectively reduce the incidence of cerebral microembolization in patients with asymptomatic CS (40) , and medical (nonsurgical) intervention alone is now more suitable for prevention of stroke associated with severe asymptomatic CS (41) . In any case, CEA produces only a modest benefit compared Table 1 Levels of evidence and grading of recommendations
Level of evidence
Grading of recommendations 1++ High-quality meta-analyses without heterogeneity; systematic reviews of RCTs each with small CI; or RCTs with very small CIs and/or very small α and β A At least one meta-analysis, systematic review, or RCT rated as 1++ and directly applicable to the target population; or a systematic review of RCTs or a body of evidence consisting principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results 1+ Well-conducted meta-analyses without clinically relevant heterogeneity; systematic reviews of RCTs; or RCTs with small CIs and/or small α and β 1− Meta analyses with clinically relevant heterogeneity, systematic reviews of RCTs with large CI, or RCTs with large CI and/or α and β B A body of evidence including studies rated as 2++, directly applicable to the target population, and demonstrating overall consistency of results; or extrapolated evidence from studies rated as 1++ or 1+ 2++ High-quality systematic reviews of case-control or cohort studies;
high-quality case-control or cohort studies with very small CIs and/or very small α and β 2+ Well-conducted case-control or cohort studies with small CIs and/or small α and β C A body of evidence including studies rated as 2+, directly applicable to the target population, and demonstrating overall consistency of results; or extrapolated evidence from studies rated as 2++ 2− Case-control or cohort studies with large CIs and/or large α and β 3
Nonanalytic studies, e.g., case reports, case series D Evidence level 3 or 4; or Evidence level 3 or 4; or Evidence from trials classified as -regardless of the level 4
Expert opinion − Meta-analyses with clinically relevant heterogeneity; systematic reviews of trials with large CIs; trials with large confidence intervals and/or large α and β with BMT alone (average annual rate of ipsilateral stroke of <1%), and produces a progressive advantage only in subsequent years (36, 41, 42) . Thus, the debate is still not over on whether BMT alone is sufficient for the prevention of stroke in patients with asymptomatic >60-70% CS (28, 43) .
CAS
CAS is an increasingly common alternative to the more traditional CEA. However, in the past, several authors have expressed reluctance to use this method on account of the risk of cerebral embolism (44) (45) (46) (47) . In CAVATAS-1 (48-50), CAVATAS-2, and ICSS (51), the incidence of stroke, death, and MI was 8·5% for CAS and 5·2% for CEA (HR 1·69, P = 0·006). The risk of any stroke was higher in the stented group. Interestingly, in the ICSS imaging substudy, magnetic resonance imaging before and after the procedure revealed a substantial excess of brain ischemic lesions in the CAS group compared with the CEA group (HR 5·2) (52) . Moreover, as reported by Rothwell, the excess procedural risk of ipsilateral ischemic stroke with CAS over CEA likely nullifies any remaining benefit of intervention vs. BMT alone in symptomatic patients, and casts serious doubts on the effectiveness of CAS in asymptomatic patients (53) .
In SAPPHIRE -which compared CAS with CEA in patients who had coexisting conditions that potentially increased the risk posed by CEA -the percentages of major adverse perioperative events with CAS and CEA were 4·8% and 9·8%, respectively (54) . The consensus was toward stenting, but this was not applicable to patients at low surgical risk. Although important criticisms of SAPPHIRE have been expressed (55) , no significant differences in the three-year outcome were reported for the two surgical procedures (56) .
Moreover, a Cochrane Review has reported no significant differences between the two techniques relative to the risk of death/ any stroke at one-month, the risk of death/stroke at 12 months, and the risk of death/any stroke/MI (57) . The only difference was, as expected, a reduced risk of cranial nerve lesions for CAS. The conclusion was, however, that due to the substantial heterogeneity of the compared studies, and because of the uncertainties about the risk of restenosis and stroke subsequent to stenting, it was not, at the moment, recommended to modify the current tendency favoring CEA to one preferring endovascular interventions as the treatment of choice for CS. Nonetheless, authoritative experts in the field have consented that primary stenting plus cerebral protection may be undertaken with a certain degree of safety in selected cases -i.e., 'high risk' patients -in experienced centers (58) . A systematic review of the literature on patient selection for CAS vs. CEA, including patients considered 'high risk' , reported that stenting was preferable in cases presenting with restenosis, tracheostomy, hostile neck, paralysis of the contralateral laryngeal nerve, or high bifurcation, and after radiotherapy of the neck (59) . In some cases, stenting is difficult to perform, and the ability and experience of the surgeon becomes of utmost importance in deciding whether to opt for CEA or medical therapy. This is frequent, especially with older patients, and is often related to the diffuse arteriopathy encountered. Old age without concomitant major comorbidity does not, per se, constitute an indication for stenting, though. A fundamental factor remains, as always, the operator and center performance in achieving an adequate quality of procedure, as underlined by American (60) and Italian (61) consensus documents.
Some randomized controlled trials (RCTs) comparing CAS with CEA have raised more doubts than certainties (62) (63) (64) (65) . For the SVS Vascular Registry, the comparison between the procedures is statistically in favor of CEA (66) . CREST reported no significant differences between CAS plus cerebral protection and CEA regarding the primary and combined death/stroke/MI endpoints at four-years (67) . However, when assessing periprocedural risks, a statistical significance between CAS and CEA was found: death was 0·7% vs. 0·3% (P = 0·18); stroke was 4·1% vs. 2·3% (P = 0·01); and MI was 1·1% vs. 2·3% (P = 0·03). More major strokes were recorded for CAS, and more cranial nerves lesions after CEA (P > 0·0001); better results were obtained with CAS in patients <70 years old, whereas CEA produced better results in >70-year-old patients. Some criticisms have been raised against CREST (68), but, nevertheless, it has been instrumental in the re-evaluation of CAS by many surgeons (69) .
Scoring systems have been proposed for periprocedural risks in CAS, such as the Siena Scoring System (70) and the one adopted in a review of SAPPHIRE (71) . Findings were consistent with observations regarding the risk factors for adverse events associated with CAS (72) (73) (74) (75) (76) (77) . In a Medicare observational study, adjusted outcomes following the procedure were worse among very-low-volume operators and early during an operator's experience (78) . However, a recent systematic review and metaanalysis of the last 13 RCTs on CEA vs. CAS has concluded that CAS has a significantly increased risk of any stroke but a decreased risk of MI (79) . Because outcome data on asymptomatic patients were sparse and imprecise, the conclusions apply primarily to symptomatic patients.
The latest Cochrane Review (80) concluded that, compared with endarterectomy, endovascular treatment is associated with an increased risk of periprocedural stroke and death. However, this excess risk appears to be limited to older patients. The longerterm efficacy of endovascular treatment and the risk of restenosis are unclear and require further follow-up of existing trials. Further trials are needed to determine the optimal treatment for asymptomatic CS.
Finally, a comparison among other international guidelines, and in particular five 2011 guidelines for the treatment of CS (ACC/AHA, SVS, ESC, Australasian, and NICE) showed that there were considerable differences between the guidelines regarding the management of both symptomatic and asymptomatic carotid patients (81) .
